Under the agreement, Zydus Lifesciences Global FZE, a wholly-owned subsidiary of Zydus Lifesciences based in the UAE, will commercialise the product in the US, while Bioeq will be responsible for its development, manufacturing, regulatory registration and supply. Shares of the Zydus Lifesciences Limited closed at ₹929.45 apiece on the NSE, up 1.23% today, December 23.
